SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aurobindo Pharma informs about press release

21 Nov 2015 Evaluate

Aurobindo Pharma has informed about a press release dated November 21, 2015, titled ‘Aurobindo Pharma receives USFDA Approval for Sildenafil Tablets’.

The above information is a part of company’s filings submitted to BSE.

Aurobindo Pharma Share Price

1560.75 7.95 (0.51%)
02-Jul-2026 12:20 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1876.35
Dr. Reddys Labs. 1350.30
Cipla 1456.55
Zydus Lifesciences 1101.85
Lupin 2395.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: